Breaking Through Overseas Expansion Barriers with On-the-Ground Expertise: Stellar Bio Recognized as

　　As the traditional Chinese medicine (TCM) industry accelerates its standardization and internationalization, the shift toward greater specialization and more sophisticated operations is becoming increasingly pronounced. A new generation of high-caliber service providers with deep regional expertise and end-to-end capabilities is emerging, injecting fresh momentum into the industry's high-quality development and overseas expansion.

　　To implement the State Council General Office's Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Sector, and to advance the sector's standardization, intelligent transformation and high-end development, the 2026 TCM Supply Chain Development Exchange Conference and the Second Symposium on Smart TCM Pharmacy Services were successfully held in Jinan on July 31, 2026.

　　Alongside the upgrading of the domestic industry, the international expansion of TCM has also reached a critical juncture. On August 1, 2026, the 2026 Summit on Practical Strategies for Bringing Chinese Patent Medicines to Southeast Asia, co-hosted by Stellar Bio and the Pharmaceutical Logistics and Supply Chain Branch of the China Federation of Logistics and Purchasing, was held in Jinan, Shandong Province. Focusing on pain points across the entire market-entry chain, real-world bottlenecks and implementation challenges confronting Chinese pharmaceutical companies in Southeast Asia, the summit directly addressed the industry's urgent internationalization needs and provided practical guidance on overcoming expansion barriers and building a lasting presence in the region. As a co-host, Stellar Bio received recognition from iiMedia Research, which named the company the “Industry Benchmark for End-to-End Commercialization Services for Chinese Pharmaceutical Companies Entering Southeast Asia.”

　　China's Chinese Patent Medicine Market Enters a Mature Phase, Making Overseas Expansion a Key Route to New Growth

　　The growth dynamics of China's Chinese patent medicine industry have fundamentally changed. As centralized procurement becomes routine, hospitals tighten cost controls and competition intensifies within an established market, the industry has moved beyond volume-led expansion and toward deeper value creation. According to iiMedia Research's 2026 White Paper on the Global Expansion of China's Chinese Patent Medicine Industry, the domestic market reached RMB 407.6 billion in 2025. Policy adjustments are expected to reduce the market to RMB 392.0 billion in 2026, marking the start of a period of consolidation and optimization. The market is projected to stabilize and recover gradually from 2027 and reach RMB 427.3 billion by 2030, with overall growth moderating and the pace of development becoming steadier.

　　As competition intensifies in this mature market, divergence among therapeutic segments and cutthroat competition driven by product homogeneity have become more pronounced. Products are highly concentrated in the three major therapeutic areas of cardiovascular and cerebrovascular diseases, respiratory diseases and digestive disorders, while barriers to competition remain relatively low across the industry. Only market-leading products with exclusive formulations, robust evidence-based clinical data and sophisticated operating capabilities are able to defend their market share; most small and medium-sized pharmaceutical companies face growth constraints.

　　These differences in competitive position have also produced a clear market hierarchy. Leading, long-established brands have the resources to expand overseas independently, while mid-sized specialty pharmaceutical companies remain focused on domestic niches. Large numbers of small and medium-sized companies, however, lack mature international operating systems and cannot independently manage the full process of overseas registration, channel development and commercialization. Demand for professional third-party pharmaceutical market-entry services is therefore continuing to rise.

　　Even as room for growth in the domestic market narrows and competition intensifies, structural changes overseas are opening a new avenue for the Chinese patent medicine industry. Historically, China's exports of Chinese patent medicines depended heavily on traditional ethnic Chinese markets such as Hong Kong. Their limited customer base and weak growth momentum could not support the industry's expansion at scale. In 2026, rapidly growing pharmaceutical markets in ASEAN countries including Indonesia, Malaysia and Vietnam are making Southeast Asia—rather than traditional ethnic Chinese markets—the principal source of incremental overseas growth for Chinese patent medicines.

　　Compared with other regions, Southeast Asia offers natural advantages for the market entry of Chinese patent medicines. Shared cultural foundations, similar disease profiles, supportive regional policies and a large population make the region fertile ground for their international expansion. Southeast Asia has a population of 685 million and a pharmaceutical market valued at USD 37.68 billion. Its compound annual growth rate of 5%–8% far exceeds the global pharmaceutical industry average, and its growth potential continues to unfold. Healthcare spending in the region is projected to exceed USD 270 billion by 2030, leaving substantial room for further expansion.

　　Yet the scale of the opportunity has also brought the industry's overseas expansion challenges into sharper relief, creating a central tension between strong demand and difficult execution. Chinese patent medicines face five principal barriers abroad: complex and differing registration requirements across jurisdictions, together with high compliance costs; limited overseas evidence-based clinical data and differences in medical understanding; inadequate intellectual property protection and frequent infringement risks; an export mix dominated by low-value raw materials; and limited brand recognition and fragmented distribution channels, which make market penetration difficult. The industry is at a difficult transition point, moving from product trading toward an enduring overseas industrial presence. Pharmaceutical companies' limited ability to expand independently has made one-stop, end-to-end and specialized commercialization support an urgent industry need.

　　Stellar Bio Builds a Region-Wide Network and an End-to-End Service Platform for Pharmaceutical Market Entry

　　Addressing the pain points and urgent market needs involved in bringing TCM and other pharmaceutical products to Southeast Asia, Stellar Bio has long focused on providing comprehensive support for cross-border market entry in the region. It is one of the few integrated Southeast Asia service providers covering four categories: innovative drugs, generic drugs, Chinese patent medicines and medical devices. With dual headquarters in Hong Kong and Singapore, Stellar Bio has operating entities in Hong Kong, Macao, Singapore, Malaysia and other key markets. Its operations cover core Southeast Asian markets including Singapore, Malaysia, Thailand and Indonesia. The company serves as a two-way bridge between pharmaceutical and medical device innovation in China and ASEAN markets, supported by a cross-border network linking China's healthcare industry with the region.

　　Unlike narrow, standardized market-entry offerings, Stellar Bio draws on years of experience in Southeast Asia and a systematic understanding of each country's regulatory policies, market-access rules and operating environment. It has established a six-part, full-lifecycle service platform covering market assessment and access strategy, regulatory registration and compliance filings, cross-border supply chains and logistics, localized commercialization and promotion, capital integration and enablement, and lifecycle operations management. Together, these capabilities create a closed loop spanning early-stage planning, implementation and long-term value creation, enabling Stellar Bio to meet the varied needs of pharmaceutical companies of different sizes and across product categories.

　　Regulatory compliance and market access are critical to launching pharmaceutical products abroad and constitute a major barrier to entering Southeast Asia. Stellar Bio has assembled a specialized regulatory and registration team led by professionals with prior experience at Singapore's Health Sciences Authority (HSA). The team has in-depth knowledge of regulatory filing standards and approval processes across Southeast Asia. It has developed parallel pathways covering conventional product registration, the Named Patient Program (NPP) special-access route and halal certification, improving submission efficiency across multiple product categories. In particular, through the NPP route, Chinese patent medicines, oncology drugs and other products that do not yet hold formal overseas marketing authorization may be supplied compliantly to named patients within approximately two months. This can help companies establish an initial presence in Southeast Asia while generating overseas clinical data to support subsequent full registration.

　　Drawing on regulatory data from multiple countries and standardized submission procedures, the team can coordinate parallel reviews across jurisdictions. By optimizing dossiers and mitigating compliance risks, Stellar Bio can reduce the overall time to overseas launch by more than 50%. The company has also prepared a dedicated Guide to Overseas Registration and Compliance for Traditional Chinese Medicine, providing pharmaceutical companies with a standardized reference for managing risks before entering international markets.

　　In supply chain development and channel execution, Stellar Bio has established pharmaceutical cold-chain hubs in relevant Southeast Asian markets, supported by integrated temperature-controlled warehousing, cross-border customs clearance and last-mile delivery services. The entire process is designed to meet local pharmaceutical regulatory standards and halal certification requirements, addressing persistent challenges in compliant cross-border storage and transportation and in fragmented logistics networks.

　　For offline distribution, the company has built a mature network spanning nine Southeast Asian countries and developed close relationships with key market participants, including public hospitals, private clinics, pharmacy chains and licensed physicians. It tailors channel strategies to the characteristics of each product: prescription medicines for cardiovascular and cerebrovascular conditions and chronic diseases are primarily introduced through hospital and clinical channels, while OTC preparations and granules are distributed through supermarkets and community pharmacies. Through a range of models—including exclusive distribution, joint channel development and equity partnerships—Stellar Bio accelerates the penetration of Chinese pharmaceutical products into Southeast Asian markets.

　　In response to the tiered structure of China's pharmaceutical industry, Stellar Bio offers three levels of customized solutions designed to match each company's needs.

　　For leading pharmaceutical companies such as Tong Ren Tang and Baiyunshan, Stellar Bio adopts a deep co-development model, offering accelerated registration, joint development of overseas manufacturing bases and high-level academic brand promotion. These services help companies localize production while leveraging ASEAN tariff policies to reduce costs and improve efficiency.

　　For mid-sized specialty pharmaceutical companies such as Yiling Pharmaceutical and Kunming Pharmaceutical Corporation, Stellar Bio offers an asset-light agency model. Stellar Bio manages the entire overseas registration, channel development and commercialization process, allowing its partners to focus on manufacturing and R&D while Stellar Bio drives registration, market entry and localized operations.

　　For the large number of small and medium-sized pharmaceutical companies, Stellar Bio provides a foundational market-entry incubation program. Its AI-powered matching system connects companies with procurement resources in Southeast Asia, helping them progress from exporting raw materials to formally registering finished dosage forms. In one renal dialysis consumables project, supply and demand were matched in just three days, reducing the sourcing cycle by 50% and significantly outperforming conventional industry approaches.

　　To support the stable execution of every stage of its clients' expansion into Southeast Asia, Stellar Bio has also developed a comprehensive enabling ecosystem. On legal matters, it works with leading international law firms, including Han Kun Law Offices, to provide services such as drafting cross-border agreements, developing global intellectual property strategies and resolving international trade disputes. On the capital side, it connects with high-quality industry investors to provide funding and industry resources for promising international pharmaceutical projects through equity investment, project joint ventures and other forms of financial support. At the industry-ecosystem level, Stellar Bio regularly hosts major events such as summits on the practical expansion of Chinese patent medicines into Southeast Asia, works with authoritative institutions to publish industry white papers, and has built a platform for dialogue, resource matching and standards development.

　　Authoritative Recognition: Industry-Benchmark Designation Underscores Stellar Bio's Core Competitiveness

　　In recognition of Stellar Bio's mature end-to-end execution capabilities, extensive practical experience in Southeast Asia and strong track record of supporting Chinese pharmaceutical companies abroad, iiMedia Research assessed and ranked the company under its evaluation framework for benchmark providers of end-to-end commercialization services to Chinese pharmaceutical companies entering Southeast Asia. The assessment covered four dimensions: commercialization capabilities, focus on target markets, commitment to commercialization services and corporate influence. Based on this assessment, iiMedia Research recognized Stellar Bio as the “Industry Benchmark for End-to-End Commercialization Services for Chinese Pharmaceutical Companies Entering Southeast Asia.” The designation recognizes Stellar Bio's overall capabilities, brand value and practical execution, and endorses the company's differentiated competitive strengths.

　　This benchmark designation reinforces Stellar Bio's position in Southeast Asia market-entry services for pharmaceuticals and medical devices, spanning innovative drugs, generic drugs, Chinese patent medicines and medical devices.

　　Stellar Bio's differentiated strengths are clear when compared with those of its peers. The company has maintained a long-term focus on Southeast Asia and on the commercialization of pharmaceuticals and medical devices, rather than pursuing an undifferentiated global footprint. This has enabled it to develop greater market depth and specialized expertise. Stellar Bio also has a dedicated registration team led by professionals with prior HSA experience, an NPP special-access pathway, and a multidimensional ecosystem of resources covering government–business coordination, capital partnerships, channel development and academic promotion. Its integrated model—combining policy navigation, localized operations and capital enablement—provides Chinese pharmaceutical companies with specialized execution support in Southeast Asia.

　　Deepening Its Southeast Asia Presence and Advancing the High-Quality Globalization of TCM

　　The internationalization of TCM has entered a pivotal stage in its transition toward high-quality development. As a major growth market, Southeast Asia is expected to maintain strong long-term momentum. Continued implementation of the Regional Comprehensive Economic Partnership (RCEP), further improvements in ASEAN pharmaceutical market-access frameworks and growing acceptance of TCM among overseas consumers will create expanding opportunities in Southeast Asia for innovative drugs, generic drugs, Chinese patent medicines and medical devices from China. The value of specialized international market-entry services will become increasingly evident.

　　Looking ahead, Stellar Bio will continue to deepen its presence in overseas markets, strengthen its international service network and standardized service platform, and upgrade its tiered market-entry solutions. Drawing on its strengths in regulatory registration, channel distribution, capital enablement and ecosystem collaboration, the company aims to lower entry barriers and compliance risks for Chinese pharmaceutical companies and accelerate the introduction of high-quality Chinese pharmaceuticals and medical devices into Southeast Asia and the wider global market. At the same time, Stellar Bio will continue to work with industry associations, authoritative institutions and industry leaders to develop standardized frameworks for the international expansion of TCM. It will help the industry move beyond a volume-led approach to overseas expansion and advance from exporting products to building brands and establishing an international industry presence, contributing to the high-quality global development of China's pharmaceutical sector.

　　About iiMedia Research

　　Founded in 2007, iiMedia Research is a leading independent data-mining and analysis institution focused on new-economy industries, as well as a national high-tech enterprise. The company independently developed—and owns all intellectual property rights in—its global big-data monitoring and analysis system. It holds five national invention patents for big-data monitoring and AI algorithms, along with more than 100 other intellectual property rights, including design patents and software copyrights. iiMedia Research has built an AI-powered data-analysis platform and offers comprehensive total addressable market (TAM), serviceable available market (SAM) and serviceable obtainable market (SOM) modeling, combining online big-data monitoring, an offline expert network and sample surveys. Guided by its mission, “Using data to make every decision evidence-based,” iiMedia Research focuses on new technologies, new consumer markets and emerging business models. Through the dual engines of big-data mining and research analysis, and with three core offerings—business trends, consumer insights and market-position services—it supports clients throughout their growth journey and helps improve business performance and strategic development.

　　iiMedia Ranking is iiMedia Research's non-commercial global evaluation platform for emerging consumer brands. Drawing on the iiMeval big-data evaluation model, it provides consumers with objective brand information and purchasing guidance. Leveraging its in-depth big-data mining and analytical capabilities, iiMedia Research continues to produce high-quality research supported by data, informed by insight and grounded in theory. Through a dual-value model combining data and strategy, it publishes more than 2,000 independent reports on emerging areas of the new economy each year. Its technology practice covers frontier sectors associated with emerging productive capacity, including mobile internet, artificial intelligence, semiconductors, advanced materials, robotics, smart hardware, aerospace, biomedicine, next-generation energy storage and intelligent driving. Its consumer practice covers food, beverages, dining, home appliances, home improvement, footwear and apparel, pharmaceuticals, beauty, pets, maternal and infant products, mobility and finance. Its emerging-business practice covers interest-driven consumption, the emotion economy, the rise of domestic brands, cross-border e-commerce, the nighttime economy, the ice-and-snow economy, the low-altitude economy, commercial aerospace and intelligent manufacturing. Tailored reports address clients' individual needs—from market-trend assessment and competitive-landscape analysis to growth-path planning—and provide an evidence base for strategic decisions, product innovation, market expansion and brand positioning. iiMedia Research's data reports, independent rankings and analyst views have been cited more than 50 million times by mainstream media, academic journals, research papers, industry reports and the financial reports of listed companies worldwide, across about 20 languages including Chinese, English, Japanese, French, Italian, German, Russian and Arabic.

　　iiMedia Research has served as an implementing organization for an outstanding key research project selected at the Ninth National Congress of the China Association for Science and Technology. It has also been recognized as a key big-data enterprise under cultivation in Guangdong Province, a benchmark innovation enterprise in Guangzhou, one of the first companies admitted to Guangzhou's artificial intelligence enterprise registry and a Guangzhou “Two Highs and Four News” enterprise. Based on its independently developed China Mobile Internet Big Data Mining and Analysis System (CMDAS)—a major project under the Guangdong Provincial Science and Technology Program (Project No. 2016B010110001)—iiMedia Research has established a multidimensional online and offline system for monitoring and analyzing macro data, business trends, market entry, competitive intelligence, business and public sentiment, consumer behavior, sales data and marketing effectiveness. It has provided ongoing big-data consulting services to more than 3,800 government and corporate organizations. iiMedia Research has also undertaken major initiatives including research projects supporting Guangzhou's development of a national science and technology think tank and projects on innovation and development in advanced manufacturing.